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doi:10.1016/j.jmii.2011.01.012Campylobacter has been recognized as the common cause of bacterial gastroenteritis in many
countries. Increasing erythromycin resistance in Campylobacter jejuni infection is noted
recently, but severe case was rarely reported. In this study, we aimed to clarify the clinical
significance of the resistant strain of C jejuni in children. We reviewed the charts of children
who were diagnosed with C jejuni enteritis in our hospital from January 2000 to December
2005, including 326 patients (117 males and 209 females). All the cases had positive stool
culture. We divided them into two groups, the sensitive group (a total of 306 cases) and resis-
tant group (a total of 20 cases), according to the drug sensitivity. We analyzed the clinical
manifestations and laboratory data between the two groups. The mean age was 3.79 3.24
years in the sensitive group and 3.03 2.84 years in the resistant group. There was no signif-
icant difference between the two groups in clinical presentations and laboratory examina-
tions. No mortality was found, and one case was initially presented with colonic
perforation. This report demonstrates that infection by erythromycin-resistant strains of C je-
juni has no clinical significance in children, despite the probably increased emergence of
erythromycin resistance.
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Figure 1. The erythromycin resistance rates for the years
2000e2005.
64 S.-M. Wang et al.Introduction
Several countries, including Canada, Japan, and Finland,
have reported Campylobacter jejuni isolates with low and
stable rates of macrolide resistance. In contrast, the
increasing level of macrolide resistance in C jejuni is
becoming a major public health concern in other parts of the
world, such as the United States, Europe, and Taiwan.1,2 The
available evidence suggests that those infectedwith resistant
strains of Campylobacter experience illness that is prolonged
and more severe than those with sensitive strains.3 However,
in comparisonwith several epidemiological studiesexamining
the clinical impact of quinolone resistance in Campylobacter
infections, there is limited information on the clinical
consequence of erythromycin resistance in Campylobacter
infection, especially in children.
In this study, focusing on C jejuni cultured from feces of
pediatric patients, we assessed the antimicrobial suscep-
tibility trends to erythromycin and its clinical significance
more than a 6-year period (2000e2005).
Methods and results
Weretrospectively reviewedthemedical charts forC jejuni in
pediatric patients from January 2000 to December 2005 at
Chang Gung Memorial Hospital, Kaohsiung Medical Center,
Taiwan. Patients were included in the study if they were
younger than 17 years of age. All patients had stool cultures
positive for C jejuni. The fecal samples were examined for
Campylobacter species by direct inoculation of feces on to
modified charcoal cefoperazone desoxycholate agar (CCDA;
Oxoid, Basingstoke, United Kingdom). The CCDA was
composed of Campylobacter growth supplement (Oxoid
SR084). The plates were incubated for 48 hours at 42C under
microaerophilic conditions (5% O2, 5% CO2, 2% H2, and 88% N2
by volume) generated by oxoid microaerophilic gas pack.
Campylobacter jejuni NCTC 11322 was incubated with each
lot of plates as a positive control. Gray, flat, and spreading
colonies, resembling those of Campylobacter, were selected
for further identification. Oxidase- and catalase-positive
colonies exhibiting a characteristic Gram stain appearance
(gram-negative S-shaped rods) were reported as Campylo-
bacter species. The ability to hydrolyze hippurate was eval-
uated by the British Standards Method (BS 5763 Part 17,
1996:9.5.5.5), and susceptibility to nalidixic acid was deter-
minedbydisk diffusionwith a 30-mg nalidixic acid disk applied
to a blood agar plate inoculated with a suspension of the test
isolate. Nalidixic acidesusceptible isolates capable of hip-
puratehydrolysiswere reportedasC jejuni,whereasnalidixic
acidesusceptible, hippurate hydrolysisenegative isolates
were reported as Campylobacter coli. Sensitivity testing for
erythromycinwas carriedout using thedisc diffusionmethod.
Clinical manifestations were recorded. Laboratory data,
including white blood cell count, platelet count, C-reactive
protein, sodium, potassium, blood urea nitrogen, sugar,
carbon dioxide, treatment modalities, complications, and
outcomes were collected.
We divided the patients into erythromycin-sensitive and
erythromycin-resistant groups according to the drug sensi-
tivity of stool culture. We analyzed differences in clinical
manifestations and laboratory data, treatment modalities,complications, and outcomes between the two groups. The
statistical analyses were performed using the Statistical
Package for Social Science (SPSS, version 13, IBM Corpora-
tion, Somers, NY 10589, USA) software package. The p
values less than 0.05 were considered statistically
significant.
A total of 326 patients (117 males and 209 females) were
enrolled in this study. The mean age at admission was
3.79 3.24 years in the sensitive group and 3.03 2.84
years in the resistant group.
There were a total of 306 cases in the sensitive group and
20 cases in the resistant group. The average rate of resistance
was 6%. As shown in Figure 1, the antimicrobial resistance
rates have increased in the past 3 years (2003e2005). There
was no significant difference between the two groups in the
laboratory profiles, including white blood cell count,
platelet, C-reactive protein, glucose, sodium, potassium,
carbon dioxide, and blood urea nitrogen levels (Table 1) or in
clinical presentations and outcomes, including vomiting,
abdominal pain, bloody diarrhea, duration of admission,
duration of diarrhea and fever before and after admission,
and symptoms of upper airway infection (Table 2). The cases
who were prescribed erythromycin were recorded. Because
this study was retrospective, the criteria of treatment were
based on the physician’s experience. Therewas no significant
difference between the two groups. In our series, no
mortality was noted in either group; however, one case in the
sensitive groupwas initially presented as colonic perforation.
Discussion
Campylobacter species are among the most frequently
identified bacterial causes of human gastroenteritis in the
United States and other industrialized countries.4 The most
important Campylobacter species is C jejuni, accounting
for more than 90% of infections.5 The increasing level of
macrolide resistance in C jejuni is becoming a major public
health concern in some parts of the world, such as the
United States, Europe, and Taiwan.1,2 Furthermore, life-
threatening systemic Campylobacter diseases are diag-
nosed more and more frequently.6 Thus, it is imperative to
investigate the clinical impact of macrolides resistance in
Campylobacter infections.
Erythromycin is considered as the drug of choice for
treating Campylobacter gastroenteritis, and ciprofloxacin
and tetracycline are used as alternative drugs.7,8 Quino-
lones and tetracycline are rarely used for treating pediatric
Table 1 Laboratory data of the patients in the erythromycin-susceptible and erythromycin-resistant groups
Laboratory data Susceptible group Resistant group p
WBC/cmm 10,088 4,304 10,456 5,304 0.744
Platelet (1,000/cmm) 26.7 8.33 25.5 7.25 0.553
CRP (mg/L) 63.2 55.6 48.1 45.3 0.272
Na (mEq/L) 137.2 3.36 137.4 3.82 0.866
K (mEq/L) 4.28 0.49 4.31 0.70 0.871
CO2 (mEq/L) 16.6 2.72 17.2 3.72 0.637
Glucose (mg/dL) 96.5 21.9 89.67 13.3 0.452
BUN (mg/dL) 9.5 4.27 10 4.24 0.873
BUNZ blood urea nitrogen; CRPZ C-reactive protein; WBCZwhite blood cell.
Campylobacter jejuni enteritis in children 65patients with Campylobacter enteritis in our cases. Thus, in
this study, we have only considered the clinical impact of
erythromycin resistance on C jejuni enteritis in children.
Since the 1990s, a significant increase in the prevalence of
resistance to macrolides among Campylobacter species has
been reported, and this is recognized as an emerging public
health problem.9 The incidence of erythromycin resistance
among C jejuni is highly variable with respect to the country
of isolation,3 ranging from 0% to 7.3%. Furthermore,
increasedmacrolide resistance among C jejuni and C coli has
been reported in both developed and developing countries,
but the situation seems to be deteriorating more rapidly in
developing countries.10 In Taiwan, a survey from1994 to 1996
shows the rate of resistance to erythromycin to be 10%.2 In
our study, the rate of erythromycin resistance is 6%, but the
resistance rate has been increasing in the past 3 years, as
shown in Figure 1. It is unknownwhether the trends displayed
for the level of antimicrobial susceptibility reported here is
the result of a biased result caused by the age of our study
subjects. Another limitation of this study was the number of
patients. In 2003, there were no erythromycin-resistant
cases, which may have confounded the reported trend of
erythromycin resistance.
In comparison with Salmonella, events of invasive illness
and death (0.63%) were more rarely associated with
Campylobacter infection.11,12 However, in adults, a number
of investigations from the United States, Thailand, and
Denmark have shown that infections with macrolide-resis-
tant Campylobacter isolates could be associated with an
increased risk of adverse events, development of invasiveTable 2 Clinical presentations of the patients in the erythromy
Clinical presentations Susceptible group
Age at ad, yr 3.79 3.24
Duration of ad, d 3.73 3.18
Duration of diarrhea before ad, d 2.65 3.96
Duration of diarrhea after ad, d 2.25 2.04
Duration of fever before ad, d 2.22 1.76
Duration of fever after ad, d 1.64 1.45
Vomiting 101/223 4
URI 94/203 4
Abdominal pain 17/91 1
Bloody diarrhea 138/172 8
Use of erythromycin 237/306 7
adZ admission; dZ days; URIZ upper respiratory tract infection; yrillness, or death compared with infections with drug-
susceptible isolates.12e14 Antimicrobial resistance can have
two effects on the outcome of infection: There can be an
accompanying change in the virulence of the organism and
there can be a poorer response to treatment because of the
choice of an empiric antimicrobial to which the organism is
resistant. In contrast to the above-mentioned reports, our
study showed that differences in duration and severity of
illness were not statistically significant between the eryth-
romycin-susceptible and the erythromycin-resistant groups.
Furthermore, the frequency of complications and long-term
sequelae (e.g. Guillain-Barre syndrome or other severe
reactive illness) did not increase in the resistant group.
Unlike in other reports, the patients in our study were all
younger than 17 years of age. There was only one case of
Campylobacter bacteremia in a patient who was aged one
andhalfmonths. He recoveredwith a treatment of ampicillin
and gentamicin. During the same period of time, we found
seven adult patients with Campylobacter bacteremia in our
hospital, and one of them was infected by an erythromycin-
resistant strain. Our data show that erythromycin-resistant
strains may not be so “virulent” in pediatric groups. Under-
lying diseases may account for the different outcomes
between adult and pediatric patients because a high
percentage of adult patients had chronic illness, such as
diabetes mellitus, cancer, and liver cirrhosis.
In summary, this report demonstrates that infection by
erythromycin-resistant strains of C jejuni has no clinical
significance in children, despite the probably increased








5.29% 7/13 53.85% 0.579
6.31% 5/11 45.45% 1.0
8.68% 2/8 25.00% 0.647
0.23% 10/10 100% 0.212
7.45% 18/20 90.00% 0.266
Z year.
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